OncoMatch/Clinical Trials/NCT04594642
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Is NCT04594642 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AZD0486 IV for b-cell non hodgkin lymphoma.
Treatment: AZD0486 IV — This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 positive
Subject must have locally confirmed CD19 positivity (must be documented after time of progression from last CD19-targeted therapy, if received)
Disease stage
Required: Stage II, III, IV
Grade: 123a (who 2016)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CD19 CAR T cell therapy
Exception: CAR T-naive subjects are allowed if they have declined, are considered ineligible for, or do not have timely access to CAR T cell therapies
CAR T-naive subjects are allowed if they have declined, are considered ineligible for, or do not have timely access to CAR T cell therapies.
Cannot have received: CD19 CAR T cell therapy
Subject received CD19 CAR T therapy within 3 months prior to first dose.
Cannot have received: peripheral autologous stem cell transplant
Subject has received a peripheral autologous stem cell transplant (SCT) within 12 weeks
Cannot have received: allogeneic stem cell transplant
an allogeneic SCT within 1 year of the first dose of study drug treatment
Cannot have received: stem cell transplant
Exception: requires ongoing immunosuppressive therapy
has received an SCT and requires ongoing immunosuppressive therapy
Lab requirements
Blood counts
anc ≥ 1000/mm3, platelets ≥ 50,000 mm3, hemoglobin ≥ 8.0 g/dl
Kidney function
egfr ≥ 50 ml/min
Liver function
total bilirubin <1.5x uln, ast/alt < 3xuln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Tampa, Florida
- Research Site · Louisville, Kentucky
- Research Site · New Brunswick, New Jersey
- Research Site · Charlotte, North Carolina
- Research Site · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify